Steris Plc Stock Price, News & Analysis

STERIS plc (NYSE: STE) reported a 1% increase in revenue to $1.22 billion for fiscal Q3 2023, compared to $1.21 billion in the previous year. Constant currency organic revenue grew 7%. Earnings per share were $1.24 as reported, with adjusted EPS at $2.02. The company experiences challenges in supply chain and a slower growth in bioprocessing, impacting overall performance. STERIS updated its fiscal 2023 outlook, now expecting 6% revenue growth (previously 8%) and adjusted EPS guidance of $8.00 to $8.10.

STERIS plc (NYSE: STE) announced a quarterly interim dividend of $0.47 per share, payable on March 23, 2023, to shareholders of record as of February 24, 2023. STERIS is recognized as a leading global provider focusing on products and services that enhance patient care and infection prevention. This dividend demonstrates the company’s commitment to returning value to shareholders while reinforcing its role in creating a healthier and safer world through innovative solutions in healthcare and life sciences.

STERIS plc (NYSE: STE) will host a conference call to discuss its fiscal 2023 third quarter financial results on February 9, 2023, at 10:00 a.m. ET. The call will be accessible via the STERIS investor relations website or by phone. A detailed press release regarding the financial results will be issued after the U.S. market closes on February 8, 2023. For those unable to attend, a replay will be available starting at noon on February 9. STERIS is recognized for its infection prevention products and services aimed at supporting patient care.

STERIS plc (NYSE: STE) reported its fiscal 2023 second quarter results, showing revenue was flat at $1.2 billion year-over-year, with a 7% increase in constant currency organic revenue. The company incurred a net loss of $315.3 million, or ($3.15) per share, due to a $490.6 million impairment charge related to its Dental segment. Adjusted earnings per diluted share remained steady at $1.99. The company anticipates foreign currency headwinds affecting revenue growth, now expected to be 8%, down from 9%. Free cash flow projections decreased to $600 million from $675 million.

STERIS plc (NYSE: STE) has declared a quarterly interim dividend of $0.47 per share, which will be paid on December 16, 2022, to shareholders on record by November 22, 2022. This reinforces STERIS's commitment to shareholder returns while they continue to provide innovative healthcare solutions focusing on infection prevention. The company is a prominent player in enhancing patient care and safety globally.

STERIS plc (NYSE: STE) will host a conference call on November 10, 2022, at 10:00 a.m. ET to discuss its fiscal 2023 second quarter financial results. A press release with these results will be released after market close on November 9, 2022. Investors can join the call via the website or by phone. A replay will be available afterward. STERIS specializes in products and services that enhance patient care and infection prevention globally. For further details, visit www.steris.com.

STERIS plc (NYSE: STE) reported a strong performance in its fiscal 2023 first quarter, ending June 30, with a 19% increase in revenue to $1.2 billion compared to $968.4 million in Q1 fiscal 2022. Adjusted EPS was $1.90, up from $1.76 a year ago. The company noted significant growth in its Healthcare segment, with a 16% revenue rise driven by consumables and capital equipment. Despite challenges, STERIS projected a 10% organic revenue growth and adjusted EPS guidance of $8.40 to $8.60 for the fiscal year.

STERIS plc (NYSE: STE) has announced a quarterly interim dividend of $0.47 per share, marking a $0.04 increase. This is the Company's 17th consecutive year of dividend growth. The dividend will be payable on September 23, 2022, to shareholders on record as of September 7, 2022. STERIS is recognized as a leading global provider of products and services aimed at enhancing patient care, particularly focusing on infection prevention.

STERIS plc (NYSE: STE) will host a conference call on August 3, 2022, at 10:00 a.m. ET to discuss its fiscal 2023 first quarter financial results. A press release with detailed results will be issued after the U.S. market closes on August 2, 2022. Investors can access the live call via the company’s website or by phone. A replay of the call will be available starting at 12:00 p.m. ET on the same day. STERIS provides innovative healthcare products and services, focusing on infection prevention to promote a healthier world.